My job depends on NIH continuing to function, but it is not immediately clear that this particular decision follows other worrying trends discussed here previously. Removing K-awards for clinical trials (but not regular, cheaper study formats) might simply be a recognition that clinical trials are too expensive for the K-format and conducting underpowered clinical trials does not help anyone much.